Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 3/20 | 0.35 |
| ▸ | CHRNA4 | P43681 | 3/20 | 0.35 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.35 |
| ▸ | CHRNB4 | P30926 | 2/20 | 0.35 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.35 |
| ▸ | FPR3 | P25089 | 1/20 | 0.33 |
| ▸ | FPR2 | P25090 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.30 |
| ▸ | KDM1A | O60341 | 1/20 | 0.30 |
| ▸ | USP2 | O75604 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6809254 | 1.00 | CHRNB2 (0.35) | CHRNB2CHRNA4CHRNA7CHRNB4CHRNA3 | |
| SCHEMBL6267443 | 1.00 | CHRNB2 (0.35) | CHRNB2CHRNA4CHRNA7CHRNB4CHRNA3 | |
| SCHEMBL6273756 | 0.82 | AAK1 (0.43) | SMN1; SMN2HSD17B10PSMB5USP2EPHX1 | |
| SCHEMBL6271562 | 0.81 | CHRNB2 (0.40) | CHRNB2CHRNA4CHRNA7CHRNB4CHRNA3 | |
| SCHEMBL6809163 | 0.81 | CHRNB2 (0.40) | CHRNB2CHRNA4CHRNA7CHRNB4CHRNA3 | |
| SCHEMBL6271761 | 0.81 | KMT2A (0.41) | SMN1; SMN2HSD17B10PSMB5EPHX1 | |
| SCHEMBL6813554 | 0.79 | FPR3 (0.38) | FPR3FPR2 | |
| SCHEMBL6274769 | 0.79 | FPR3 (0.38) | FPR3FPR2 | |
| SCHEMBL6274792 | 0.77 | AAK1 (0.40) | SMN1; SMN2HSD17B10PSMB5USP2TSHR | |
| SCHEMBL20177411 | 0.77 | PREP (0.33) | CHRNB2CHRNA4CHRNA7CHRNB4CHRNA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040077618-A1 | Cycloalkylamides and their therapeutic applications | ABBOTT LABORATORIES | 2004-04-22 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040077618-A1 | Cycloalkylamides and their therapeutic applications | GAP43, SCN1B, GRIN2B | CHRNB2 170/4885CHRNA4 191/4885CHRNA7 149/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.